CN105873945B - 工程化的高亲和力人类t细胞受体 - Google Patents

工程化的高亲和力人类t细胞受体 Download PDF

Info

Publication number
CN105873945B
CN105873945B CN201480071620.2A CN201480071620A CN105873945B CN 105873945 B CN105873945 B CN 105873945B CN 201480071620 A CN201480071620 A CN 201480071620A CN 105873945 B CN105873945 B CN 105873945B
Authority
CN
China
Prior art keywords
tcr
cell
modified
cells
cell receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480071620.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105873945A (zh
Inventor
希娜·N·史密斯
丹尼尔·T·哈里斯
大卫·M·克兰泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CN105873945A publication Critical patent/CN105873945A/zh
Application granted granted Critical
Publication of CN105873945B publication Critical patent/CN105873945B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480071620.2A 2013-11-22 2014-11-21 工程化的高亲和力人类t细胞受体 Active CN105873945B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
US61/907,887 2013-11-22
PCT/US2014/066892 WO2015077607A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Publications (2)

Publication Number Publication Date
CN105873945A CN105873945A (zh) 2016-08-17
CN105873945B true CN105873945B (zh) 2020-07-17

Family

ID=53180203

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480071620.2A Active CN105873945B (zh) 2013-11-22 2014-11-21 工程化的高亲和力人类t细胞受体
CN201480071635.9A Expired - Fee Related CN105899530B (zh) 2013-11-22 2014-11-21 工程化的高亲和力人类t细胞受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480071635.9A Expired - Fee Related CN105899530B (zh) 2013-11-22 2014-11-21 工程化的高亲和力人类t细胞受体

Country Status (20)

Country Link
US (4) US10023625B2 (OSRAM)
EP (2) EP3071594A4 (OSRAM)
JP (4) JP6476182B2 (OSRAM)
KR (2) KR102415259B1 (OSRAM)
CN (2) CN105873945B (OSRAM)
AU (4) AU2014352826B2 (OSRAM)
BR (1) BR112016011567A2 (OSRAM)
CA (2) CA2930847A1 (OSRAM)
DK (1) DK3071593T3 (OSRAM)
ES (1) ES2729406T3 (OSRAM)
IL (2) IL245468B (OSRAM)
MX (3) MX383471B (OSRAM)
PL (1) PL3071593T3 (OSRAM)
PT (1) PT3071593T (OSRAM)
RU (2) RU2729383C2 (OSRAM)
SA (1) SA516371174B1 (OSRAM)
SG (2) SG10201804335QA (OSRAM)
TR (1) TR201908404T4 (OSRAM)
WO (2) WO2015077607A1 (OSRAM)
ZA (2) ZA201603116B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP3071594A4 (en) 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
CN108601849A (zh) * 2015-09-22 2018-09-28 尤利乌斯·马克西米利安维尔茨堡大学 一种在淋巴细胞中高水平的和稳定的基因转移的方法
US12364757B2 (en) 2015-10-01 2025-07-22 Ospedale San Raffaele S.R.L TCR and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3394092A1 (en) * 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3042890A1 (en) 2016-11-14 2018-05-17 Fred Hutchinson Cancer Research Center High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof
MX2019010972A (es) * 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
CN110785432B (zh) * 2017-04-24 2024-12-27 圣拉斐尔医院有限责任公司 Tcr和肽
JP7181517B2 (ja) 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
CN112739339B (zh) * 2018-07-23 2024-12-27 海德堡医药研究有限责任公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
CN114555790B (zh) * 2019-08-20 2025-02-25 弗雷德哈钦森癌症中心 Wt-1特异性t细胞免疫疗法
CN115335404A (zh) * 2020-02-12 2022-11-11 艾伯维公司 双特异性结合分子
KR20230002554A (ko) 2020-04-28 2023-01-05 아킬레스 테라퓨틱스 유케이 리미티드 T 세포 요법
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
WO2022214835A1 (en) 2021-04-09 2022-10-13 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
JP2024524185A (ja) 2021-06-22 2024-07-05 アキレス セラピューティクス ユーケー リミテッド 抗原特異的ｔ細胞を生成するための方法
KR20240046834A (ko) * 2021-07-19 2024-04-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Fanci, rad51, 및 pbk 항원을 표적화하는 펩타이드 및 가공된 t 세포 수용체 및 이의 사용 방법
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574906A (zh) * 2009-07-03 2012-07-11 英美偌科有限公司 T细胞受体
CN103097407A (zh) * 2010-07-28 2013-05-08 英美偌科有限公司 T细胞受体

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
ATE370967T1 (de) 1998-10-21 2007-09-15 Altor Bioscience Corp Polyspezifische bindemoleküle und deren verwendung
ATE290020T1 (de) * 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1549748B1 (en) 2002-10-09 2014-10-01 Immunocore Ltd. Single chain recombinant t cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
ATE408684T1 (de) 2004-05-19 2008-10-15 Medigene Ltd Verfahren zur verbesserung von t-zellrezeptoren
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
EP2352756B1 (en) * 2008-11-24 2012-09-19 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH High affinity t cell receptor and use thereof
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US9409969B2 (en) 2009-02-09 2016-08-09 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
BR112013006718B1 (pt) 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
RU2018130123A (ru) * 2012-05-03 2018-11-07 Фред Хатчинсон Кансэр Рисёч Сентер Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
EP3071594A4 (en) 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
WO2016022400A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574906A (zh) * 2009-07-03 2012-07-11 英美偌科有限公司 T细胞受体
CN103097407A (zh) * 2010-07-28 2013-05-08 英美偌科有限公司 T细胞受体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《Changing T cell specificity by retroviral T cell receptor display》;Helmut W H G Kessels et al;《PNAS》;20001219;第96卷(第26期);第14578-14583页 *
《MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors》;Leisegang et al;《The Journal Of Clinical Investigation》;20101031;第120卷(第11期);第3869-3877页 *

Also Published As

Publication number Publication date
RU2729383C2 (ru) 2020-08-06
BR112016011567A2 (pt) 2017-10-24
ES2729406T3 (es) 2019-11-04
IL245467A0 (en) 2016-06-30
US20190055298A1 (en) 2019-02-21
KR102415259B1 (ko) 2022-06-30
WO2015077615A1 (en) 2015-05-28
JP6697386B2 (ja) 2020-05-20
US10023625B2 (en) 2018-07-17
JP6970724B2 (ja) 2021-11-24
CN105899530B (zh) 2020-05-08
SA516371174B1 (ar) 2019-04-14
JP2017501129A (ja) 2017-01-12
AU2014352834A1 (en) 2016-05-26
US20160280756A1 (en) 2016-09-29
NZ719720A (en) 2020-09-25
SG10201804335QA (en) 2018-06-28
MX2016006625A (es) 2016-12-02
RU2740648C2 (ru) 2021-01-19
SG10201804330YA (en) 2018-07-30
AU2014352826B2 (en) 2019-08-01
KR20160087866A (ko) 2016-07-22
US20160280755A1 (en) 2016-09-29
DK3071593T3 (da) 2019-06-11
CA2930852A1 (en) 2015-05-28
EP3071594A4 (en) 2017-05-03
BR112016011583A2 (pt) 2017-09-26
RU2016124179A (ru) 2017-12-27
JP2020007374A (ja) 2020-01-16
TR201908404T4 (tr) 2019-07-22
NZ719707A (en) 2020-09-25
MX383471B (es) 2025-03-14
IL245468B (en) 2020-10-29
JP6476182B2 (ja) 2019-02-27
AU2019272003A1 (en) 2019-12-19
AU2014352834B2 (en) 2019-08-29
AU2014352826A1 (en) 2016-05-26
KR20160085345A (ko) 2016-07-15
AU2021202274A1 (en) 2021-05-06
IL245467B (en) 2020-04-30
RU2016124163A (ru) 2017-12-27
CA2930852C (en) 2024-01-23
ZA201603169B (en) 2020-05-27
MX371202B (es) 2020-01-22
US10344075B2 (en) 2019-07-09
IL245468A0 (en) 2016-06-30
US20220396606A1 (en) 2022-12-15
EP3071593A4 (en) 2017-05-03
WO2015077607A1 (en) 2015-05-28
JP2022023196A (ja) 2022-02-07
PL3071593T3 (pl) 2019-11-29
MX2021006932A (es) 2021-07-07
ZA201603116B (en) 2018-12-19
JP2017501130A (ja) 2017-01-12
CA2930847A1 (en) 2015-05-28
CN105899530A (zh) 2016-08-24
MX2016006620A (es) 2017-05-11
EP3071593B1 (en) 2019-03-13
EP3071594A1 (en) 2016-09-28
AU2019272003B2 (en) 2021-05-06
EP3071593A1 (en) 2016-09-28
PT3071593T (pt) 2019-06-27
CN105873945A (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
US20220396606A1 (en) Engineered high-affinity human t cell receptors
JP6454394B2 (ja) Ｔ細胞受容体の操作
CA2880098C (en) Engineering t-cell receptors
HK1228412A1 (en) Engineered high-affinity human t cell receptors
HK1228412B (en) Engineered high-affinity human t cell receptors
NZ719720B2 (en) Engineered human t cell receptors with high affinity for wt1
BR112016011583B1 (pt) Receptores de célula t humana de alta afinidade geneticamente modificados e seus usos
NZ719707B2 (en) Engineered human t cell receptors with high affinity for binding survivin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant